UPDATE: Targacept Official Release Confirms Phase 2b Trial in TC-1734 Did Not Show Superiority to Donepezil
July 14, 2014 at 15:07 PM EDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced top-line ...